2016 Hematological Malignancies
BV + AVD vs. ABVD in frontline advanced cHL
Brentuximab Vedotin 1,2 mg/kg q2w + AVD 28-day cycles
E V A L U A T I O
R A N D O M I Z
E
N
ABVD 28-day cycles
* Assessment based on Revised Response Criteria for Malignant Lymphoma
Younes et al, ASCO 2013; Chicago, US (Abstract #TPS8612)
Made with FlippingBook